medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2009, Number 3

<< Back Next >>

Rev Mex Oftalmol 2009; 83 (3)

Hallazgos en el electrorretinograma multifocal (ERGmf) posterior a la aplicación de bevacizumab (Avastin) intravítreo

Cubas-Lorenzo V, Torres-Soriano M, Díaz-Rubio JL, Kon-Jara V, Fromow-Guerra J, Quiroz-Mercado H, Jiménez-Sierra JM

Language: Spanish
References: 18
Page: 162-166
PDF size: 186.99 Kb.


ABSTRACT

Introduction: There are few papers regarding electrophysiological findings after intravitreal application of bevacizumab. We sought to determine the safety and toxicity in a short term follow-up as determined by multifocal electroretinogram (mfERG).
Methods: 31 eyes with diverse retinal pathology treated with intravitreal bevacizumab (2.5 mg/0.1 cc) underwent baseline and one month follow-up mfERG.
The P1 wave response was analyzed measuring density, amplitude and implicit time.
Results: The changes observed in the electrophysiologic response were not statistically significant; finding a p value ›0.05 for all variables analyzed.
Discussion: The use of intravitreal bevacizumab has become widespread without clinical evidence of its safety. There is evidence of damage to ganglion cells and to the retinal pigment epithelium which are not amenable to measurement by mfERG.
Conclusions: The results suggest there is no significant change in the retinal electrophysiological response in a short term follow-up with the use of intravitreal bevacizumab, however, it is not possible to determine retinal toxicity with this study.


REFERENCES

  1. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002; 2:795-803.

  2. Tombran-Tink J, Barnstable C. Ocular Angiogenesis. Humana Press. Totowa, New Jersey 2006.

  3. Aiello LP, Pierce EA, Foley ED y cols. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92:10457-10461.

  4. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42:2408-2413.

  5. Shahar J, Avery RL, Heilweil G y cols. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26:262-269.

  6. Hood D, Bach M y cols. ISCEV Guidelines for clinical multifocal electroretinography (2007 edition). ISCEV: www.iscev.org.

  7. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1999; 40:2638-2651.

  8. Kretschmann U, Bock M, Gockeln R, Zrenner E. Clinical applications of multifocal electroretinography. Doc Ophthalmol 2000; 100:99-113.

  9. Palmowski AM, Sutter EE, Bearse MA Jr, Fung W. Mapping of retinal function in diabetic retinopathy using the multifocal electroretinogram. Invest Ophthalmol Vis Sci 1997; 38:2586-2596.

  10. Hood DC, Greenstein V, Frishman L y cols. Identifying inner retinal contributions to the human multifocal ERG. Vision Res 1999; 39:2285-2291.

  11. Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci 2002; 43:1673-1685.

  12. Maturi RK, Bleau LA, Wilson DL y cols. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26(3):270-274.

  13. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.

  14. Pai SA, Setty R, Vijayan PB y cols. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007; 143(4):601-606.

  15. Heiduschka P, Julien S, Hofmeister S y col. Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 2008; 28(1):46-55.

  16. Food and Drug Administration (FDA). www.fda.gov.

  17. Bakri S, Snyder M y cols. Six-Month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26:519-522.

  18. Nishijima K, Ng YS, Zhong L y cols. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007; 171(1):53-67.




2020     |     www.medigraphic.com